Ask AI
Optimization of Adjuvant CDK46 Therapy
Translating Evidence Into Practice: Pharmacist-Led Optimization of Adjuvant CDK4/6 Therapy in High-Risk HR+/HER2- Early Breast Cancer

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

K.H. is a 33-year-old premenopausal woman diagnosed with stage IIIB HR-positive/HER2-negative invasive ductal carcinoma with a 7-cm tumor and 2 positive lymph nodes​. She has been presented with options to initiate ribociclib or abemaciclib in addition to endocrine therapy​. As the pharmacist in the clinic, you have been asked to discuss the differences between the 2 to assist with the patient’s decision-making.

In discussions with patients considering adjuvant CDK4/6inhibitors, which of the following would be accurate to tell them regarding the efficacy endpoints for their respective trials?

How confident are you in your answer?
2.

A.F. is a 42-year-old premenopausal woman diagnosed with stage IIIA HR-positive/HER2-negative invasive ductal carcinoma. Initial imaging revealed a 5.2-cm tumor and 1 positive axillary lymph node with micrometastatic involvement (N1mi)​.


She received neoadjuvant ddAC/T, which was well tolerated​.


She presents to the clinic after pathology from her bilateral mastectomy revealed treatment response with a decrease in tumor size to 3 cm and no remaining lymph node disease, corresponding to a pathologic stage IIA disease​


At today’s office visit, an ECG is obtained, revealing a QTcF of 460 ms.

Which of the following adjuvant CDK4/6 inhibitors is the most appropriate choice for this patient?

How confident are you in your answer?
3.

J.C. is a 56-year-old postmenopausal woman with pT2N1 HR-positive/HER2-negative early breast cancer. She completed AC-T and started on letrozole + adjuvant abemaciclib therapy 10 days ago​.


Her baseline labs are normal​.


Today she reports loose stools (3-4/day above baseline) since Day 3; she is taking fluids but no added antidiarrheal yet.​


CBC today shows ANC 0.95 x 109/L, although she is afebrile and well-appearing.

J.C. is expressing concern about “being on this medication for 2 years if this diarrhea keeps happening.” Beyond antidiarrheal therapy, what pharmacist-led strategy is most likely to prevent treatment interruption?

How confident are you in your answer?
4.

A.C. is a 58-year-old woman receiving adjuvant ribociclib + ET who presents at Month 4 with grade 3 neutropenia (ANC 800/µL) but is otherwise asymptomatic. She is highly motivated to continue therapy but is concerned about the dose changes affecting efficacy.

What is the most appropriate pharmacist-led intervention?

How confident are you in your answer?